Retatrutide is a novel investigational drug designed to treat obesity and other metabolic disorders such as type 2 diabetes. It is a tri-agonist, meaning it activates three different hormone receptors simultaneously. Specifically, retatrutide targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, all of which play crucial roles in regulating metabolism, appetite, and blood sugar levels
